Search

Introduction: Imidapril data are favorable, showing that presents an appropriate metabolic profile in patients with metabolic syndrome or glucose intolerance. However, there are few data in real-life treatments with imidapril compared with other angiotensin-converting enzyme inhibitors (ACE I). In this paper, we compared a group of diabetic hypertensive patients receiving imidapril with another group receiving enalapril for the treatment of hypertension and value the impact on glycosylated haemoglobin (Hb A1c) over several months. Objectives: To study the effect on glycaemic control and renal function following the treatment with imidapril or enalapril in hypertensive diabetic patients (PHD). Materials and Methods: We studied 56 PHD (68 5 years, 36 women and 25 men) who were treated with imidapril (30 P) or enalapril (26P) in addition to the usual treatment their doctor considered it necessary to maintain BP 120 / 80 controls on the office. All underwent a A1cHb and glycaemic control at the beginning, first, two and 6 months, end of the study with a 24 hr, microalbuminuria (Mcalb).,at the beginning and the end to the study. The results were compared and shown in the following table

The purpose of the study was to determine the prognostic value of ventricular-arterial coupling (VAC) in patients with arterial hypertension and stable heart failure with reduced ejection fraction (HFrEF). Methods: In prospective study (follow-up 12-24 months, median 18 months) prognosis of 93 stable patients (75% male, age 64 9 years (M SD), history of myocardial infarction 67%, diabetes mellitus 32%, heart rate 75 13/min) with controlled hypertension (blood pressure (BP)